Tiago Biachi, MD, PhD

Cancer Focus:
Colorectal Cancer, Pancreatic Cancer

Dr. Tiago Biachi de Castria is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Dr. Biachi de Castria received his MD degree from Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil. He also obtained a Doctorate degree in Internal Medicine and Therapeutics from São Paulo Federal University. He completed his Residency in Internal Medicine at São Paulo Federal University and his Clinical Oncology Fellowship at the São Paulo University - São Paulo Cancer Institute. Dr. Biachi de Castria was an attending in the Gastrointestinal Oncology Service at the São Paulo Cancer Institute and Sírio-Libanês Hospital. In 2021, he obtained the title of Associate Professor in Gastroenterology Service (São Paulo University) and Associate Professor in Postgraduate Course in Medical Oncology (São Paulo University). Dr. Biachi de Castria most recently completed a one-year Advanced Fellowship in Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Dr. Tiago Biachi de Castria’s clinical and research interest are in colorectal and hepatobiliary cancers, including biomarkers and drug development.

 

Clinical Trial 22565
Evaluation of the clinical outcomes of immune checkpoint blockade in MUTYH associated colorectal cancer patients.
Condition: Gastrointestinal Tumor
Status: Open

Clinical Trial 23188
A Phase II Study of Enfortumab Vedotin in Patients with Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: Enfortumab Vedotin (Padcev)
Status: Open

Clinical Trial 23233
Evaluating the correlation between clonal hematopoiesis chemotherapy induced peripheral neuropathy in patients with gastrointestinal malignancies exposed to oxaliplatin
Condition: Gastrointestinal Tumor
Status: Open

Clinical Trial 23309
A Platform Study of RAS(ON) Inhibitors to Treat Patients with Gastrointestinal Solid tumor - SUB-A: Study of RMC-6236 in Combination with 5-flourouracil-based regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB: Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB-C: Study of RMC-6236 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - SUB-D: Study of RMC-9805 with or without RMC-6236 in Combination with 5-flourouracil-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-E: Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-F: Study of RMC-9805 With or Without RMC-6236 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with RAS G12D-Mutant Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Avastin (Bevacizumab); Bevacizumab (); CPT-11 (irinotecan); Camptosar (irinotecan); Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); RMC-6236 (Daraxonrasib); RMC-9805 (); Zoldonrasib (); eloxatin (Oxaliplatin); gemcitabine (); irinotecan (); leucovorin (); mFOLFIRINOX (); mFOLFOX6 ()
Status: Open

Clinical Trial 23375
Phase II Study of NALIRIFOX (Nanoliposomal Irinotecan + Oxaliplatin with Fluorouracil and Folinic Acid) in Advanced Unresectable Small Bowel Tumors
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Nanoliposomal Irinotecan (); Oxaliplatin (); eloxatin (Oxaliplatin); leucovorin ()
Status: Open

Clinical Trial 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); gemcitabine (); mFOLFOX6 ()
Status: Open

Clinical Trial 23539
Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer
Condition: Gastrointestinal Tumor
Status: Open

Clinical Trial 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Davis EW, Park MA, Basinski TL, Arnoletti JP, Bloomston M, Carson TL, Biachi De Castria T, Chen DT, Cortizas EM, Crowder SL, Genilo-Delgado M, Douglas WG, Huguet KL, Jiang K, Hodul PJ, Karolak A, Kim DW, Koomen JM, Menon AA, Mo Q, Mok SR, Molina-Vega MA, Moreno-Urazan L, Ahmed S, Parker NH, Pimiento JM, Rasool G, Sparks LM, Stewart PA, Tassielli AF, Teer JK, Trevino JG, Velanovich V, Wang X, Whelan CJ, Judge SM, Judge AR, Fleming JB, Malafa MP, Jeong D, Permuth JB. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep.34(9):1609-1617. Pubmedid: 40553455.
• de Castria TB, Lenz G, Valagni G, Kim RD. Role of neoadjuvant therapies in locally advanced colon cancer. Chin Med J (Engl). 2025 Sep.138(17):2091-2101. Pubmedid: 40736234. Pmcid: PMC12407165.
• DeSomma A, Maletz S, Basinski TL, Morales R, de Castria TB, Bloomston M, Chen DT, Douglas WG, Huguet KL, Jeong D, Jiang K, Kim DW, Luthra A, Pimiento JM, Rajasekhara S, Velanovich V, Park MA, Shields GS, Slavich GM, Permuth JB. Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative. BMC Cancer. 2025 Oct.25(1):1530. Pubmedid: 41062956. Pmcid: PMC12506433.
• Valagni G, Lenz G, Biachi de Castria T. Frontline Therapy in Advanced Hepatocellular Carcinoma. Touch Rev Oncol Haematol. 2025 Oct.21(2).
• Lin YC, Turner K, Rajasekhara S, Kim DW, de Castria TB, Nguyen OT, Hume E, Sprow O, Santiago C, Milano J, Riccardi D, Nardella N, Al-Jumayli M, Permuth JB, Hoffe S, Hembree T, Hong YR, Islam JY, Tabriz AA, Hodul PJ. Early Supportive and Nutritional Care For Adults With Pancreatic Cancer: A Pilot Study. J Pain Symptom Manag. 2025 Nov.70(5):490-502. Pubmedid: 40816695.
• Yu J, Laborde JM, Park R, Shahzad M, Kim Y, Cheon J, Imanirad I, Kim RD, Biachi de Castria T, Nardella NL, Malafa M, Denbo JW, Fleming JB, Hoffe SE, Frakes JM, Sinnamon AJ, Pimiento JM, Hodul PJ, Kim DW. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507279. Pmcid: PMC12153592.
• Hendrick LE, Naffouje S, Imanirad I, Pereira AL, Biachi T, Sanchez J, Dessureault S, Stefanou A, Dineen SP, Felder S. Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity-Matched Analysis. J Surg Oncol. 2025 May.131(6):1090-1100. Pubmedid: 39658830.
• de Castria TB, Kim RD. Safety of current treatments for advanced cholangiocarcinoma. Expert Opin Drug Saf. 2025 Mar.24(3):251-259. Pubmedid: 39718803.
• Harada G, de Castria TB, Moraes FY. Genomic Testing in Brazil: Navigating Challenges and Harnessing Opportunities for Global Health Impact. JCO Glob Oncol. 2025 Jan.11:e2400545. Pubmedid: 39746170.
• Permuth J, Park M, Davis E, Alhassan S, Arnoletti J, Basinski T, McKee A, Bloomston M, Carson T, de Castria TB, Chen DT, Cortizas E, Crowder S, Delgado MG, Douglas W, Fleming J, Hodul P, Huguet K, Jiang K, Kim DW, Koomen J, Luthra A, Malafa M, Menon A, Morales R, Merchant N, Meredith K, Mo Q, Molina-Vega M, Moreno-Urazan L, Olumoyin K, Parker N, Pimiento J, Rasool G, Rejniak K, Sansil S, Sparks L, Stewart P, Tassielli A, Teer J, Tran DV, Trevino J, Velanovich V, Whelan C, Jeong D, Judge S, Judge A. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Res Sq. 2025 Feb. Pubmedid: 39989973. Pmcid: PMC11844656.
• Lenz G, Pereira RA, Valagni G, Biachi de Castria T. Adjuvant Anti-Inflammatory Therapy in Postoperative Colorectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Colorectal Cancer. 2025 Dec.24(4):415-424.e2. Pubmedid: 40940200.
• Biachi T, Shostak J. Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations. Clin Adv Hematol Oncol. 2025 Dec.23(9 Suppl 11):1-12. Pubmedid: 41467919.
• Pereira RA, Barcellos G, Lenz G, Pereira AAL, Biachi de Castria T. Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis. J Surg Oncol. 2025 Dec. Pubmedid: 41424434.
• Buonopane IR, Saldanha EF, de Menezes JSA, da Conceição LD, Reis CMP, Leite LF, Francischetto T, Peixoto RD, Biachi de Castria T. Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis. Brit J Cancer. 2025 Dec. Pubmedid: 41402557.
• Park MA, Davis EW, Alhassan S, Arnoletti JP, Basinski TL, McKee AB, Bloomston M, Carson TL, Biachi de Castria T, Chen DT, Cortizas EM, Crowder SL, Delgado MG, Douglas WG, Fleming JB, Hodul P, Huguet KL, Jiang K, Kim DW, Koomen J, Luthra AK, Malafa M, Menon AA, Morales R, Merchant NB, Meredith K, Mo Q, Molina-Vega MA, Moreno-Urazan L, Olumoyin KD, Parker N, Pimiento JM, Rasool G, Rejniak KA, Sansil S, Sparks LM, Stewart P, Tassielli AF, Teer JK, Tran DV, Trevino JG, Velanovich V, Whelan CJ, Jeong D, Judge SM, Judge AR, Permuth JB. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Commun Med (Lond). 2025 Dec.6(1):19. Pubmedid: 41413302. Pmcid: PMC12789063.
• Leite LF, Noronha MM, de Menezes JSA, da Conceição LD, Almeida LFC, Cappellaro AP, Belotto M, Biachi de Castria T, Peixoto RD, Megid TBC. Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers (Basel). 2025 Aug.17(17). Pubmedid: 40940901. Pmcid: PMC12427569.
• Biachi de Castria T, Kim RD. Adding pieces to immunotherapy puzzle in biliary tract cancer. AME Clinical Trials Review. 2024 Oct.2.
• Valagni G, Becham Ndemazie N, Biachi de Castria T. Trifluridine/Tipiracil and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer. Touch Rev Oncol Haematol. 2024 Nov.20(2).
• Protásio BM, de Castria TB, Natalino R, Mangone FR, Saragiotto DF, Sabbaga J, Hoff PM, Chammas R. Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort. Clin Colorectal Cancer. 2024 Mar.23(1):73-84. Pubmedid: 38151358.
• Biachi de Castria T, Kim RD. Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights. Pragmat Obs Res. 2024 Jun.15:79-87. Pubmedid: 38881691. Pmcid: PMC11178097.
• Permuth JB, Park MA, Chen DT, Basinski T, Powers BD, Gwede CK, Dezsi KB, Gomez M, Vyas SL, Biachi T, Cortizas EM, Crowder S, Genilo-Delgado M, Green BL, Greene A, Gregg C, Hoffe SE, Jiang K, Kim B, Vasudevan V, Garcialopez De Llano J, Menon AA, Mo Q, MorenoUrazan LM, Mok S, Parker N, Rajasekhara S, Rasool G, Sinnamon A, Sparks L, Stewart PA, Tardif K, Tassielli AF, Teer JK, Tran DV, Turner KL, Vadaparampil ST, Whelan CJ, Douglas WG, Velanovich V, Karachristos A, Legaspi A, Meredith K, Molina-Vega MA, Huguet KL, Arnoletti JP, Bloomston M, Trevino J, Merchant NB, Pimiento JM, Hodul PJ, Malafa M, Fleming J, Judge SM, Jeong DK, Judge A. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma. Front Oncol. 2024 Jul.14:1362244. Pubmedid: 39109281. Pmcid: PMC11300308.
• Biachi de Castria T, Kim RD. Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter]. Pragmat Obs Res. 2024 Jul.15:91-92. Pubmedid: 39006513. Pmcid: PMC11246625.
• de Moraes FCA, Pasqualotto E, Chavez MP, Ferreira ROM, De Castria TB, Burbano RMR. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2024 Feb.24(1):240. Pubmedid: 38383390. Pmcid: PMC10882870.
• Zhu J, Wu Y, Ji P, Qi J, Yang X, Pocha C, Tustumi F, Biachi de Castria T. Identification of a prognostic disulfidptosis-related gene signature in hepatocellular cancer. J Gastrointest Oncol. 2024 Aug.15(4):1647-1656. Pubmedid: 39279954. Pmcid: PMC11399847.
• Jayakrishnan T, Baca Y, Xiu J, Patel M, Weinberg BA, Lou E, Datta J, Khushman M, Gulhati P, Goel S, Biachi de Castria T, Florou V, Nair KG, Kamath SD, Khorana AA. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers. JCO Precis Oncol. 2024 Aug.8:e2400138. Pubmedid: 39102632.
• Cao JZ, Wang CQ, Shi Z, Song JY, Tustumi F, de Castria TB, Wu J, Pocha C, Tsilimigras DI, Wang ZH, Tao T, Lu J. NOVA2 regulates the properties of liver cancer stem cells and lenvatinib resistance in hepatocellular carcinoma via the Wnt pathway. J Gastrointest Oncol. 2024 Aug.15(4):1674-1685. Pubmedid: 39279925. Pmcid: PMC11399850.
• Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. Contemp Clin Trials Commun. 2024 Apr.38:101271. Pubmedid: 38440777. Pmcid: PMC10910065.
• Biachi de Castria T, Miao R, Kim RD. Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer. touchREVIEWS in Oncology & Haematology. 2024 Apr.20(1):20-24.
• Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, Cunha L, Mekonnen HD, Diop PS, Elwakil R, Ali MM, Ndlovu N, Ndumbalo J, Makondi PT, Tzeuton C, Biachi de Castria T, Agyei-Nkansah AA, Balogun F, Bougouma A, Atipo Ibara BI, Jonas E, Kimani S, Kingham P, Kurrimbukus R, Hammad N, Fouad M, El Baghdady N, Servais Albert Fiacre EB, Sewram V, Spearman CW, Yang JD, Roberts LR, Abdelaziz AO. Africa Guidelines for Hepatocellular Carcinoma Buildup Process. JCO Glob Oncol. 2023 Sep.9:e2300159. Pubmedid: 37944087. Pmcid: PMC10645406.
• Maron SB, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, Do RKG, Paroder V, Pandit-Taskar N, Lewis JS, Biachi De Castria T, Sabwa S, Socolow F, Feder L, Thomas J, Schulze I, Kim K, Elzein A, Bojilova V, Zatzman M, Bhanot U, Nagy RJ, Lee J, Simmons M, Segal M, Ku GY, Ilson DH, Capanu M, Hechtman JF, Merghoub T, Shah S, Schultz N, Solit DB, Janjigian YY. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. Clin Cancer Res. 2023 Sep.29(18):3633-3640. Pubmedid: 37406106. Pmcid: PMC10502449.
• Khasawneh H, Ferreira Dalla Pria HR, Miranda J, Nevin R, Chhabra S, Hamdan D, Chakraborty J, Biachi de Castria T, Horvat N. CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Status and Perspective on the Use of Radiomics. J Clin Med. 2023 Oct.12(21). Pubmedid: 37959287. Pmcid: PMC10649102.
• Queiroz MM, Lima NF, Biachi de Castria T. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza. Cancers (Basel). 2023 Mar.15(7). Pubmedid: 37046631. Pmcid: PMC10093144.
• Capareli F, Costa F, Tuszynski JA, Sousa MC, Setogute YC, Lima PD, Carvalho L, Santos E, Gumz BP, Sabbaga J, de Castria TB, Jardim DL, Freitas D, Horvat N, Bezerra ROF, Testagrossa L, Costa T, Zanesco T, Iemma AF, Abou-Alfa GK. Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma. Cancer Med. 2023 Jun.12(11):12402-12412. Pubmedid: 37184216. Pmcid: PMC10278519.
• Webking S, Sandoval ML, Chuong MD, Ucar A, Aparo S, De Zarraga F, Sahin I, Biachi T, Kim DW, Hoffe SE, Frakes JM, Palm RF. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Cancer Control. 2023 Jan.30. Pubmedid: 38038261. Pmcid: PMC10693219.
• Yan T, Huang C, Peng C, Duan X, Ji D, Duan Y, Zhang W, Zhao H, Gao K, Yang X, Zhang L, Cheng J, de Castria TB, Pocha C, Tsilimigras DI, Wu T, Su G, Li Y, Yu L, Lu Y. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Ann Transl Med. 2023 Jan.11(2):109. Pubmedid: 36819518. Pmcid: PMC9929741.
• Li J, Zhang D, Liu H, Wang D, Pan C, Biachi de Castria T, Mok SRS, Zhou Z, Yan C. Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment. J Gastrointest Oncol. 2023 Dec.14(6):2559-2573. Pubmedid: 38196528. Pmcid: PMC10772702.
• Miranda J, Causa Andrieu P, Nincevic J, Gomes de Farias LP, Khasawneh H, Arita Y, Stanietzky N, Fernandes MC, De Castria TB, Horvat N. Advances in MRI-Based Assessment of Rectal Cancer Post-Neoadjuvant Therapy: A Comprehensive Review. J Clin Med. 2023 Dec.13(1). Pubmedid: 38202179. Pmcid: PMC10780006.
• de Castria TB, Khalil DN, Harding JJ, O'Reilly EM, Abou-Alfa GK. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncol. 2022 Oct.18(33):3769-3782. Pubmedid: 36399155.
• Huang E, Ma T, Zhou J, Ma N, Yang W, Liu C, Hou Z, Chen S, de Castria TB, Zeng B, Zong Z, Zhou T. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. Ann Transl Med. 2022 Jul.10(14):766. Pubmedid: 35965795. Pmcid: PMC9372681.
• Pereira MA, Ramos MFKP, Dias AR, Ribeiro R, Cardili L, Zilberstein B, Cecconello I, Ribeiro U, de Mello ES, de Castria TB. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Arch. 2021 Jun.478(6):1039-1048. Pubmedid: 33098489.
• Dornellas AFL, Ramos MFKP, Pereira MA, Cardili L, Dias AR, de Castria TB. Locally Advanced Gastric Adenocarcinoma with Impressive Response to Hemostatic Radiation: the Possible Role of p53 Status and Eosinophilic Infiltrate. J Gastrointest Cancer. 2021 Jun.52(2):788-791. Pubmedid: 32954464.
• Pereira MA, de Castria TB, Ramos MFKP, Dias AR, Cardili L, de Moraes RDR, Zilberstein B, Nahas SC, Ribeiro U, de Mello ES. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression. J Surg Oncol. 2021 Dec.124(7):1040-1050. Pubmedid: 34255356.
• de Castria TB, Tang L, Queiroz MM, Awni BM, Paroder V, Shamseddine A, Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. J Gastrointest Oncol. 2021 Dec.12(6):3123-3132. Pubmedid: 35070435. Pmcid: PMC8748022.
• Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, de Castria TB, Zilberstein B, Nahas SC, Ribeiro U, de Mello ES. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Med Sci (Basel). 2021 Dec.10(1). Pubmedid: 35076580. Pmcid: PMC8788521.
• Harada G, Bonadio RRDCC, de Araújo FCC, Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR, de Castria TB. Induction Chemotherapy for Locally Advanced Esophageal Cancer. J Gastrointest Cancer. 2020 Jun.51(2):498-505. Pubmedid: 31240598.
• Ramos MFKP, Duarte VC, Pereira MA, de Castria TB, Schmerling CK, Zilberstein B, Ribeiro-Júnior U, Cecconello I. Schistosomiasis Misleading Gastric Cancer Treatment. J Gastrointest Cancer. 2020 Jun.51(2):643-646. Pubmedid: 31758467.
• Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, Hoff PMG, Ribeiro U, Cecconello I. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. J Gastrointest Surg. 2020 Jan.24(1):19-27. Pubmedid: 31745892.
• Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2020 Jan.1(1):CD009256. Pubmedid: 31930743. Pmcid: PMC6956680.
• Ramos MFKP, Pereira MA, de Castria TB, Ribeiro RRE, Cardili L, de Mello ES, Zilberstein B, Ribeiro-Júnior U, Cecconello I. Remnant gastric cancer: a neglected group with high potential for immunotherapy. J Cancer Res Clin Oncol. 2020 Dec.146(12):3373-3383. Pubmedid: 32671505.
• Charruf AZ, Ramos MFKP, Pereira MA, Dias AR, de Castria TB, Zilberstein B, Cecconelo I, Ribeiro U. Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case-control study. J Surg Oncol. 2020 Apr.121(5):833-839. Pubmedid: 31943232.
• Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, Charruf AZ, de Castria TB, Zilberstein B, Ceconello I, Avancini Ferreira Alves V, Ribeiro U, de Mello ES. Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer. J Surg Oncol. 2020 Apr.121(5):795-803. Pubmedid: 31773740.
• Ramos MFKP, Pereira MA, Amorim LC, de Mello ES, Faraj SF, Ribeiro U, Hoff PMG, Cecconello I, de Castria TB. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?. J Surg Oncol. 2020 Apr.121(5):804-813. Pubmedid: 31797380.
• Victor CR, Fujiki FK, Takeda FR, Hoff PMG, de Castria TB. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. J Glob Oncol. 2019 Jul.5:1-10. Pubmedid: 31365299. Pmcid: PMC6775989.
• Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Ribeiro RRE, de Castria TB, Zilberstein B, Alves VAF, Ribeiro U, de Mello ES. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Mol Diagn Ther. 2019 Dec.23(6):761-771. Pubmedid: 31595457.
• Mota BS, Riera R, Ricci MD, Barrett J, de Castria TB, Atallah ÁN, Bevilacqua JL. Nipple- and areola-sparing mastectomy for the treatment of breast cancer. Cochrane Database Syst Rev. 2016 Nov.11(11):CD008932. Pubmedid: 27898991. Pmcid: PMC5868722.
• Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database Syst Rev. 2015 Oct.2015(10):CD010463. Pubmedid: 26482542. Pmcid: PMC6759539.
• de Castria TB, Rodrigues SR, Diz Mdel P. Late isolated central nervous system relapse from ovarian serous adenocarcinoma: a case report and literature review. Case Rep Obstet Gynecol. 2014 Dec.2014:297307. Pubmedid: 25506007. Pmcid: PMC4251821.
• de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013 Aug.(8):CD009256. Pubmedid: 23949842.

Dr. Tiago Biachi is on the medical review board at HealthCentral Corp. and has reviewed several articles related to gastrointestinal cancers.